

Standalone Unaudited Financial Results for the Quarter & Half Year Ended on 30/09/2012							
PART-I							(₹ in Lacs)
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30/9/12	30/6/12	30/9/11	30/9/12	30/9/11	31/3/12
		Unaudited					Audited
1	Income from Operations						
	(a) Net Sales/Income from Operations (Net of Excise Duty)	1966.22	1478.83	1722.11	3445.05	2966.50	5947.87
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	33.95
	Total Income from Operations (Net)	1966.22	1478.83	1722.11	3445.05	2966.50	5981.82
2	Expenses						
	(a) Cost of Materials Consumed	677.78	512.68	640.19	1190.46	1007.28	1917.93
	(b) Purchases of Stock in Trade	0.20	0.58	91.69	0.78	91.93	91.93
	(c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	-14.61	-36.61	-54.31	-51.22	20.40	-41.60
	(d) Employee benefits Expense	443.31	383.20	330.74	826.51	619.20	1268.89
	(e) Depreciation and amortisation Expense	26.00	24.00	31.39	50.00	55.39	121.77
	(f) Other Expenses (Any Item exceeding 10% of the total expense relating to continuing operations to shown separately)	516.65	450.31	358.85	966.96	714.50	1797.62
	Total Expenses	1649.33	1334.16	1398.55	2983.49	2508.70	5156.54
3	Profit / (Loss) from Operations before other income, finance cost and exceptional items (1-2)	316.89	144.67	323.56	461.56	457.80	825.28
4	Other Income	11.74	6.77	-3.70	18.51	1.24	81.52
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items (3+4)	328.63	151.44	319.86	480.07	459.04	906.80
6	Finance Cost	26.21	23.46	17.39	49.67	29.53	62.79
7	Profit / (Loss) from ordinary activities after finance cost but before exceptional items (5-6)	302.42	127.98	302.47	430.40	429.51	844.01
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	8.05
9	Profit / (Loss) from Ordinary activities before tax (7+8)	302.42	127.98	302.47	430.40	429.51	852.06
10	Tax Expense	75.00	45.00	82.50	120.00	117.50	252.54
11	Net Profit / (Loss) from Ordinary activities after tax (9-10)	227.42	82.98	219.97	310.40	312.01	599.52
12	Extra ordinary items (Net of tax expense Rs.)						
13	Net Profit / (Loss) for the period (11+12)	227.42	82.98	219.97	310.40	312.01	599.52
14	Paid-up Equity Share Capital (face value of Rs.10/- each.)	464.93	464.93	464.93	464.93	464.93	464.93
15	Reserves and surplus	0.00	0.00	0.00	0.00	0.00	1405.58
	Earnings per share (EPS)						
	a) EPS (before & after extra ordinary items-Basic & Diluted)	4.89	1.78	4.73	6.68	6.71	12.89



PART - II INFORMATION FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2012.							
Sr. No.	Particulars	Quarter Ended			Half year Ended		Year Ended
		30/9/12	30/6/12	30/9/11	30/9/12	30/9/11	31/3/12
		Unaudited					Audited
A.	Particulars of Shareholding						
1	Public shareholding						
	- Number of shares	2528763	2539468	2564586	2528763	2564586	2549497
	- Percentage of shareholding	54.39	54.62	55.16	54.39	55.16	54.84
2	Promoters and Promoter Group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	0	0	0	0	0	0
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0	0	0
	- Percentage of shares (as a % of the total share capital of the company)						
	b) Non - encumbered						
	- Number of shares	2120537	2109832	2084714	2120537	2084714	2100103
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	45.61	45.38	44.84	45.61	44.84	45.17
	Particulars	30.09.2012					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter				Nil		
	Received during the quarter				5		
	Disposed of during the quarter				5		
	Remaining unresolved at the end of the quarter				Nil		
Notes:							
1. The above unaudited results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 31.10.2012.							
2. The Limited Review of the above results has been carried out by the Statutory Auditors.							
3. Figures of previous quarters / year are re-grouped/re-arranged, wherever necessary.							
4. The Company is dealing exclusively in pharmaceuticals formulation business segment, hence segmentwise presentation of financial result is not required.							



Statement of Asset & Liabilities as at 30.09.2012			
			(₹ in Lacs)
Particulars		30/9/12	31.3.12
A. EQUITY & LIABILITIES			
1 Share Holders Fund			
a) Share Capital	464.93		464.93
b) Reserves & Surplus	1715.99		1405.58
Sub-total Shareholders' fund		2180.92	1870.51
2 Non Current Liabilities			
a) Long Term Borrowings	245.61		6.80
b) Deferred Tax Liability (Net)	115.15		115.15
c) Other Long Term Liabilities	250.38		242.81
d) Long Term Provisions	712.27		460.99
Sub total Non-current liabilities		1323.41	825.74
3 Current Liabilities			
a) Short Term Borrowings	216.70		231.79
b) Trade Payables	499.25		228.33
c) Other Current Liabilities	461.61		434.23
d) Short Term Provisions	120.64		441.67
Sub total Current liabilities		1298.20	1336.02
TOTAL -EQUITY AND LIABILITIES		4802.53	4032.28
B. ASSETS			
1 Non Current Assets			
a) Fixed Assets			
b) Tangible Assets	1284.23		1304.21
c) Intangible Assets	7.83		7.80
d) Capital Work In Progress	140.66		23.87
e) Intangible Assets under development	0.00		0.00
f) Non Current Investments	63.14		52.80
g) Deferred Tax Assets (Net)	0.00		0.00
h) Long Term Loans & Advances	0.00		0.00
i) Other Non Current assets	0.00		0.00
Sub total Non-current assets		1495.86	1388.68
2 Current Assets			
a) Current Investments	0.00		0.00
b) Inventories	742.44		627.76
c) Trade Receivables	688.86		368.31
d) Cash & Cash Equivalents	928.12		793.25
e) Short Term Loans & Advances	40.90		38.22
f) Other Current Assests	906.35		816.06
Sub total - Current assets		3306.67	2643.60
TOTAL ASSETS		4802.53	4032.28
		By order of the Board,	
Place : Mumbai		For Jenburkt Pharmaceuticals Ltd.	
Date : 31/10/2012		<i>Uttam N. Bhuta</i>	
		(Uttam N. Bhuta)	
		Chairman and Managing Director.	



LIMITED AUDIT REVIEW REPORT

Review Report To The Board of Directors,
JENBURKT PHARMACEUTICALS LTD,
Nirmala Apartments, 93, J.P.Road,
Andheri (W),
Mumbai-400 058.


We have reviewed the accompanying statement of unaudited financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended on 30th September, 2012 (1st July, 2012 to 30th September, 2012), except for the disclosures regarding 'Public Shareholding' and 'Promoter' and 'Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Revised Standard on Review Engagements 2400, 'Engagements to Review Financial Statements', issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying financial statements do not give a true and fair view (or are not presented fairly, in all material respects) in accordance with Financial Reporting Standards.

For D.L.Arora & Co.
Chartered Accountants
Firm Regn No.: 100545W

Dilip Arora
Proprietor
M. No.: 036152



Place : Mumbai.

Date: 30/10/2012.